Varian to Acquire Boston Scientific’s Oncology Assets for $90M

Shots:

• Varian acquires the Boston Scientific drug-loadable microsphere (Oncozene/Embozene Tandem) and bland embolic (Embozene) bead products for the treatment of arteriovenous malformations and hypervascular tumors for $90M
• The focus of the acquisition is to expand Varian’s interventional oncology portfolio and to get benefits from the acquired product’s regulatory clearances in 35+ countries globally
• Varian plans to manufacture & distribute the products without acquiring Boston Scientific operations. The transaction is expected to close on Aug’2019

Click here to read full press release/ article | Ref: Varian | Image: Glassdoor